Reuters logo
BRIEF-Bavarian Nordic: positive data from Phase 2 study of a universal RSV vaccine
June 27, 2017 / 12:07 PM / 4 months ago

BRIEF-Bavarian Nordic: positive data from Phase 2 study of a universal RSV vaccine

June 27 (Reuters) - BAVARIAN NORDIC A/S

* REG-BAVARIAN NORDIC ANNOUNCES POSITIVE DATA FROM ONGOING PHASE 2 STUDY INVESTIGATING A UNIVERSAL RSV VACCINE

* SAYS ‍RESULTS CONFIRM INDUCTION OF ANTIBODIES (IGA) ASSOCIATED WITH MUCOSAL RESPONSES​

* ‍SAYS VACCINE WAS SHOWN TO BE BOTH WELL TOLERATED AND IMMUNOGENIC AT BOTH DOSE LEVELS INVESTIGATED.​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below